Well, maybe not, it's a "blueprint"....so a goal, and going by MSBs history, on manufacturing, likely to fall short.
You can clearly see it in the quarterlies all year, incl. US$11,494 just in SEP Q
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS, page-434
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.116B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.5¢ | $1.473M | 1.509M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 72372 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 15823 | 25 |
View Market Depth
| Last trade - 15.24pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |